Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 9Ovarian Neoplasms 1Neoplasm Metastasis 1Fallopian Tube Neoplasms 1Estrogen Receptor Positive 1Endometrial Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Brain Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1

Interventions

Tamoxifen 6Specimen Handling 4Neoadjuvant Therapy 3Radiotherapy 2Chemotherapy, Adjuvant 2Biopsy 2Anastrozole 2trastuzumab biosimilar HLX02 1sargramostim 1exemestane 1UAB 30 1Trastuzumab 1Surgical Procedures, Operative 1Sulindac 1Polymerase Chain Reaction 1PF-05280014 1Ontruzant 1Omacor 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Lapatinib 1In Situ Hybridization, Fluorescence 1Immunohistochemistry 1Immunoenzyme Techniques 1High-Energy Shock Waves 1HER2 peptide (369-377) 1Granulocyte-Macrophage Colony-Stimulating Factor 1Fulvestrant 1Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Intraductal, Noninfiltrating × Fulvestrant × Clear all
NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

National Cancer Institute (NCI)

Phase NA Unknown
100 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡